Interview

The Australian Government has given approval to proceed with the implementation of enhanced transparency measures for prescription medicines, in response to public demand for more information on prescription medicines that are under evaluation.

Noxopharm (ASX:NOX) has lodged a pre-Investigational New Drug (pre-IND) submission with the US FDA for a clinical trial of its Veyonda in patients with COVID-19 infection.

Australian venture capital firm OneVentures has announced the appointment of John Westwater and Kelly Constable to its healthcare team.

Australian medical technology company 4DMedical (formerly known as 4Dx) says it has received clearance from the FDA to market its four-dimensional XV Technology lung imaging product - XV Lung Ventilation Analysis Software.

Australia does not have a comparative advantage in the manufacturing of pharmaceuticals but it could still be a national priority for the federal government, according to industry minister Karen Andrews.

Melbourne-based therapeutic antibody development company Patrys (ASX:PAB) has announced the inventor of the Deoxymab technology platform, Dr James Hansen of the Yale School of Medicine, has been awarded a research grant from the US National Institutes of Health.

ResApp Health (ASX:RAP) says its ResAppDx-EU smartphone-based acute respiratory diagnostic test has been under evaluation at a federal government-funded COVID-19 respiratory clinic in Brisbane for the past month.

AusBiotech welcomes Michelle McMurry-Heath, immunologist and former FDA official, who will succeed Jim Greenwood as new CEO of Biotechnology Innovation Organization on 1 June 2020.

Cochlear (ASX:COH) has announced that the US Court of Appeals for the Federal Circuit in Washington DC has denied its petition for a rehearing of an appeal against a judgement involving patent infringement.

Health minister Greg Hunt has announced a round of funding from the Medical Research Future Fund’s Biomedical Translation Bridge will be committed to COVID-19 treatments.

Almac Clinical Services says it has commenced a number of research projects on behalf of organisations related to COVID-19 treatment options.

Noxopharm (ASX:NOX) has announced a $7.9 million capital raise its says will go towards progressing its oncology programs as well as its recent move into infection.